medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2007, Number 3

<< Back Next >>

Arch Neurocien 2007; 12 (3)

Neural tube defects. Experience in a hospital in Toluca, Mexico

González-Vargas O, Trejo-Lucero H

Language: Spanish
References: 23
Page: 171-175
PDF size: 53.63 Kb.


ABSTRACT

Mexico is the second country of the world most frequently of defects of the neural tube (DTN). These sufferings must to imperfections in the embryogenesis; its incidence can diminish with the folic acid provision. In our country, the incidence reports show numbers of the 5 to 25 born cases by 10.000 alive ones; the international numbers are of 1 case by 10, 000 births. In our means reports of the DTN do not exist. Material and methods: in a cross-sectional descriptive study, we investigated the characteristic epidemiological of the DTN taken care of in the Hospital Materno Infantil Josefa Ortiz de Domínguez (SSa) in Toluca city, between years 2000-2006. Results. 42 cases of DTN studied. All the cases came from rural or semi urban means. The age average of the mother was of 24 years. Only 3 (7%) mothers before referred to have consumed acid folic during the pregnancy. The main defect was myelomeningocele (76%). Most of them were seen in our hospital with the broken meningeo coat; this defect was associated with hydrocephalic in a 78%. Conclusions. The characteristic epidemiologists of our patients show one serious absence of folic acid ingestion in the mothers. Given the population that is taken care of in our hospital, all the cases were of rural places. The clinical characteristics are similar to the reported thing internationally. A serious defect in the initial attention of the DTN exists and it does not exist a program of pursuit and direction.


REFERENCES

  1. Moore CA, Li S, Li Z. Elevated rates of severe neural tube defects in a high-prevalence area in northern China. Am J Med Genet 1997;73:113-8.

  2. Botto LD, Moore CA, Khoury MJ, Ericsson JD. Neural Tube Defects. N Eng J Med 1999; 341(20):1509-19.

  3. Sadler TW. Mechanisms of neural tube closure and defects. Ment Retard Dev Disabil Res Rev 1998;4:247-53.

  4. French BM. Midline fusion defects and defects of formation. In: Youmans JR, editor. Neurological surgery. Philadelphia: WB Saunders 1982; 1236-380.

  5. Berry RJ, Li Z, Erickson JD, et al. Preventing neural-tube defects with folic acid in China. N Engl J Med 1999;341:1485-90.

  6. Moore CA, Li S, Li Z. Elevated rates of severe neural tube defects in a high-prevalence area in northern China. Am J Med Genet 1997;73:113-8.

  7. Lemire RJ. Neural tube defects. JAMA 1988;259:558-62.

  8. Ruiz MC, Fernández QG, Luna GP, Tapia CR. Panorama epidemiológico de los defectos del tubo neural en México. Gac Med Mex 1995; 131:48.

  9. Morales AE, Ruíz MC, Tapia CR. Manual para la vigilancia epidemiológica de los defectos del tubo neural. México. Dirección General de Epidemiología. Secretaría de Salud. 1995.

  10. Holmes LB, Driscoll SG, Atkins L. Etiologic heterogeneity of neural tube defects. N Engl J Med 1976;294:365-9.

  11. Sean D, Scout JM. The prevention of neural tube defects. Curr Op Obst Ginecol 1998; 10(2): 85-9.

  12. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-137.

  13. Rothenberg SP, da Costa MP, Sequeiro JM. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural tube defect. N Engl J Med 2004; 350: 134-42.

  14. Finnell RH, Gould A, Spiegelstein O. Pathobiology and genetics of neural tube defects. Epilepsia 2003; 44(3):14-23.

  15. Chistensen B, Arbour L, Tran P. Genetic polymorphisms in methylenetetrahydrofolate reductasa and methionine cintaza, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 1999; 84:151-7.

  16. Norgaard-Pedersen B, Bagger P, Bang J. Maternal serum alphafetoprotein screening for fetal malformations in 28,062 pregnancies. Acta Obstet Gynecol Scan 1985;64: 511-4.

  17. Lennon CA, Gray DL. Sensitivity and specificity of ultrasound for the detection of neural tube and ventral wall defects in a high-risk population. Obstet Gynecol 1999; 94:562-6.

  18. Charney EB, Weller SC, Sutton LN, Bruce DA, Schut LB. Management of the newborn with myelomeningocele: time for a decision making process. Pediatrics 1985;75:58-64.

  19. Stein SC, Schut L. Hydrocephalus in myelomeningocele. Childs Brain 1979;5:413-9.

  20. McLone DG, Dias MS. Complications of myelomeningocele closure. Pediatr Neurosurg 1991;17:267-73.

  21. Leck I. The geographical distribution of neural tube defects and oval clefts. BMJ 1984;40: 390-5.

  22. Muñoz-Juárez S, Vargas H, Hernández B, López O, Ortiz RM. Frecuencia y algunos factores de riesgo de mortalidad en el estado de Hidalgo, México, por defectos de cierre del tubo neural. Salud Pub Mex 2002; 44:422-30.

  23. Rukaiya KA, Hamid, Philippa Newfield. Pediatric Neuroanesthesia. Neural Tube Defects. Anesthesiol Clin North Am 2001; 19: 1-4.




2020     |     www.medigraphic.com